GSDMD and prostate carcinoma: Gao et al. developed prostate-specific membrane antigen (PSMA)-targeting EVs expressing scFv fragments and loaded with gasdermin D-N-terminal (GSDMD), which induced pyroptosis in PSMA+ prostate cancer cells, activating antitumor immunity and suppressing tumor growth [162].